Global Recombinant FSH Injections Supply, Demand and Key Producers, 2024-2030

Publication ID:

GIR032402610

Publication Date:

March 6, 2024

Pages:

103

Publisher:

GIR

Countries:

Global [1]

USD 4,480.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Recombinant FSH Injections market size is expected to reach $ million by 2030, rising at a market growth of % CAGR during the forecast period (2024-2030).
The fertility preservation and infertility treatment market has witnessed significant growth in recent years, driven by factors such as increasing infertility rates, delayed pregnancies, advancements in assisted reproductive technologies (ART), and growing awareness. Fertility preservation technologies, including egg freezing and sperm banking, have gained popularity among individuals seeking to preserve their reproductive potential. In the infertility treatment segment, in vitro fertilization (IVF), intrauterine insemination (IUI), and other ART procedures have become mainstream options. Future developments are anticipated in areas such as personalized medicine, gene editing technologies, and improved success rates in ART procedures. The market is likely to see ongoing advancements, innovations, and collaborations aimed at addressing infertility challenges and expanding the range of options available to individuals and couples.
Follicle Stimulating Hormone (FSH) injections are pharmaceutical preparations containing the hormone FSH, a crucial component in the regulation of reproductive processes. FSH is produced by the pituitary gland and plays a key role in the stimulation of ovarian follicles in females and sperm production in males. FSH injections are commonly used in assisted reproductive technologies, such as in vitro fertilization (IVF), to enhance the development and maturation of multiple follicles in the ovaries. In fertility treatments, these injections help regulate and stimulate the ovaries to produce more eggs, increasing the chances of successful fertilization and pregnancy.
Human follicle stimulating hormone (FSH) includes urinary human follicle stimulating hormone (uFSH) and recombinant FSH (rFSH). According to expert consensus, recombinant follicle-stimulating hormone is available in two dosage forms: powder injection and water injection.
This report studies the global Recombinant FSH Injections production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Recombinant FSH Injections, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2023 as the base year. This report explores demand trends and competition, as well as details the characteristics of Recombinant FSH Injections that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Recombinant FSH Injections total production and demand, 2019-2030, (K Units)
Global Recombinant FSH Injections total production value, 2019-2030, (USD Million)
Global Recombinant FSH Injections production by region & country, production, value, CAGR, 2019-2030, (USD Million) & (K Units)
Global Recombinant FSH Injections consumption by region & country, CAGR, 2019-2030 & (K Units)
U.S. VS China: Recombinant FSH Injections domestic production, consumption, key domestic manufacturers and share
Global Recombinant FSH Injections production by manufacturer, production, price, value and market share 2019-2024, (USD Million) & (K Units)
Global Recombinant FSH Injections production by Type, production, value, CAGR, 2019-2030, (USD Million) & (K Units)
Global Recombinant FSH Injections production by Application production, value, CAGR, 2019-2030, (USD Million) & (K Units).
This reports profiles key players in the global Recombinant FSH Injections market based on the following parameters 鈥� company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Gonal-F (Merck), Follistim (Organon), Bravelle (Ferring), Menopur (Ferring), Fostimon (IBSA), Puregon (Organon), BEMFOLA (Gedeon Richter), Follitrope (LG Chem) and GenSci, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Recombinant FSH Injections market.
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2019-2030 by year with 2023 as the base year, 2024 as the estimate year, and 2025-2030 as the forecast year.
Global Recombinant FSH Injections Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World
Global Recombinant FSH Injections Market, Segmentation by Type
Powder
Liquid
Global Recombinant FSH Injections Market, Segmentation by Application
IVF and Embryo Transfer
Infertility Treatment
Companies Profiled:
Gonal-F (Merck)
Follistim (Organon)
Bravelle (Ferring)
Menopur (Ferring)
Fostimon (IBSA)
Puregon (Organon)
BEMFOLA (Gedeon Richter)
Follitrope (LG Chem)
GenSci
Key Questions Answered
1. How big is the global Recombinant FSH Injections market?
2. What is the demand of the global Recombinant FSH Injections market?
3. What is the year over year growth of the global Recombinant FSH Injections market?
4. What is the production and production value of the global Recombinant FSH Injections market?
5. Who are the key producers in the global Recombinant FSH Injections market?

Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.

Table Of Contents:

1 Supply Summary
1.1 Recombinant FSH Injections Introduction
1.2 World Recombinant FSH Injections Supply & Forecast
1.2.1 World Recombinant FSH Injections Production Value (2019 & 2023 & 2030)
1.2.2 World Recombinant FSH Injections Production (2019-2030)
1.2.3 World Recombinant FSH Injections Pricing Trends (2019-2030)
1.3 World Recombinant FSH Injections Production by Region (Based on Production Site)
1.3.1 World Recombinant FSH Injections Production Value by Region (2019-2030)
1.3.2 World Recombinant FSH Injections Production by Region (2019-2030)
1.3.3 World Recombinant FSH Injections Average Price by Region (2019-2030)
1.3.4 North America Recombinant FSH Injections Production (2019-2030)
1.3.5 Europe Recombinant FSH Injections Production (2019-2030)
1.3.6 China Recombinant FSH Injections Production (2019-2030)
1.3.7 Japan Recombinant FSH Injections Production (2019-2030)
1.4 Market Drivers, Restraints and Trends
1.4.1 Recombinant FSH Injections Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Recombinant FSH Injections Major Market Trends
2 Demand Summary
2.1 World Recombinant FSH Injections Demand (2019-2030)
2.2 World Recombinant FSH Injections Consumption by Region
2.2.1 World Recombinant FSH Injections Consumption by Region (2019-2024)
2.2.2 World Recombinant FSH Injections Consumption Forecast by Region (2025-2030)
2.3 United States Recombinant FSH Injections Consumption (2019-2030)
2.4 China Recombinant FSH Injections Consumption (2019-2030)
2.5 Europe Recombinant FSH Injections Consumption (2019-2030)
2.6 Japan Recombinant FSH Injections Consumption (2019-2030)
2.7 South Korea Recombinant FSH Injections Consumption (2019-2030)
2.8 ASEAN Recombinant FSH Injections Consumption (2019-2030)
2.9 India Recombinant FSH Injections Consumption (2019-2030)
3 World Recombinant FSH Injections Manufacturers Competitive Analysis
3.1 World Recombinant FSH Injections Production Value by Manufacturer (2019-2024)
3.2 World Recombinant FSH Injections Production by Manufacturer (2019-2024)
3.3 World Recombinant FSH Injections Average Price by Manufacturer (2019-2024)
3.4 Recombinant FSH Injections Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Recombinant FSH Injections Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Recombinant FSH Injections in 2023
3.5.3 Global Concentration Ratios (CR8) for Recombinant FSH Injections in 2023
3.6 Recombinant FSH Injections Market: Overall Company Footprint Analysis
3.6.1 Recombinant FSH Injections Market: Region Footprint
3.6.2 Recombinant FSH Injections Market: Company Product Type Footprint
3.6.3 Recombinant FSH Injections Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 United States VS China VS Rest of the World
4.1 United States VS China: Recombinant FSH Injections Production Value Comparison
4.1.1 United States VS China: Recombinant FSH Injections Production Value Comparison (2019 & 2023 & 2030)
4.1.2 United States VS China: Recombinant FSH Injections Production Value Market Share Comparison (2019 & 2023 & 2030)
4.2 United States VS China: Recombinant FSH Injections Production Comparison
4.2.1 United States VS China: Recombinant FSH Injections Production Comparison (2019 & 2023 & 2030)
4.2.2 United States VS China: Recombinant FSH Injections Production Market Share Comparison (2019 & 2023 & 2030)
4.3 United States VS China: Recombinant FSH Injections Consumption Comparison
4.3.1 United States VS China: Recombinant FSH Injections Consumption Comparison (2019 & 2023 & 2030)
4.3.2 United States VS China: Recombinant FSH Injections Consumption Market Share Comparison (2019 & 2023 & 2030)
4.4 United States Based Recombinant FSH Injections Manufacturers and Market Share, 2019-2024
4.4.1 United States Based Recombinant FSH Injections Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Recombinant FSH Injections Production Value (2019-2024)
4.4.3 United States Based Manufacturers Recombinant FSH Injections Production (2019-2024)
4.5 China Based Recombinant FSH Injections Manufacturers and Market Share
4.5.1 China Based Recombinant FSH Injections Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Recombinant FSH Injections Production Value (2019-2024)
4.5.3 China Based Manufacturers Recombinant FSH Injections Production (2019-2024)
4.6 Rest of World Based Recombinant FSH Injections Manufacturers and Market Share, 2019-2024
4.6.1 Rest of World Based Recombinant FSH Injections Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Recombinant FSH Injections Production Value (2019-2024)
4.6.3 Rest of World Based Manufacturers Recombinant FSH Injections Production (2019-2024)
5 Market Analysis by Type
5.1 World Recombinant FSH Injections Market Size Overview by Type: 2019 VS 2023 VS 2030
5.2 Segment Introduction by Type
5.2.1 Powder
5.2.2 Liquid
5.3 Market Segment by Type
5.3.1 World Recombinant FSH Injections Production by Type (2019-2030)
5.3.2 World Recombinant FSH Injections Production Value by Type (2019-2030)
5.3.3 World Recombinant FSH Injections Average Price by Type (2019-2030)
6 Market Analysis by Application
6.1 World Recombinant FSH Injections Market Size Overview by Application: 2019 VS 2023 VS 2030
6.2 Segment Introduction by Application
6.2.1 IVF and Embryo Transfer
6.2.2 Infertility Treatment
6.3 Market Segment by Application
6.3.1 World Recombinant FSH Injections Production by Application (2019-2030)
6.3.2 World Recombinant FSH Injections Production Value by Application (2019-2030)
6.3.3 World Recombinant FSH Injections Average Price by Application (2019-2030)
7 Company Profiles
7.1 Gonal-F (Merck)
7.1.1 Gonal-F (Merck) Details
7.1.2 Gonal-F (Merck) Major Business
7.1.3 Gonal-F (Merck) Recombinant FSH Injections Product and Services
7.1.4 Gonal-F (Merck) Recombinant FSH Injections Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.1.5 Gonal-F (Merck) Recent Developments/Updates
7.1.6 Gonal-F (Merck) Competitive Strengths & Weaknesses
7.2 Follistim (Organon)
7.2.1 Follistim (Organon) Details
7.2.2 Follistim (Organon) Major Business
7.2.3 Follistim (Organon) Recombinant FSH Injections Product and Services
7.2.4 Follistim (Organon) Recombinant FSH Injections Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.2.5 Follistim (Organon) Recent Developments/Updates
7.2.6 Follistim (Organon) Competitive Strengths & Weaknesses
7.3 Bravelle (Ferring)
7.3.1 Bravelle (Ferring) Details
7.3.2 Bravelle (Ferring) Major Business
7.3.3 Bravelle (Ferring) Recombinant FSH Injections Product and Services
7.3.4 Bravelle (Ferring) Recombinant FSH Injections Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.3.5 Bravelle (Ferring) Recent Developments/Updates
7.3.6 Bravelle (Ferring) Competitive Strengths & Weaknesses
7.4 Menopur (Ferring)
7.4.1 Menopur (Ferring) Details
7.4.2 Menopur (Ferring) Major Business
7.4.3 Menopur (Ferring) Recombinant FSH Injections Product and Services
7.4.4 Menopur (Ferring) Recombinant FSH Injections Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.4.5 Menopur (Ferring) Recent Developments/Updates
7.4.6 Menopur (Ferring) Competitive Strengths & Weaknesses
7.5 Fostimon (IBSA)
7.5.1 Fostimon (IBSA) Details
7.5.2 Fostimon (IBSA) Major Business
7.5.3 Fostimon (IBSA) Recombinant FSH Injections Product and Services
7.5.4 Fostimon (IBSA) Recombinant FSH Injections Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.5.5 Fostimon (IBSA) Recent Developments/Updates
7.5.6 Fostimon (IBSA) Competitive Strengths & Weaknesses
7.6 Puregon (Organon)
7.6.1 Puregon (Organon) Details
7.6.2 Puregon (Organon) Major Business
7.6.3 Puregon (Organon) Recombinant FSH Injections Product and Services
7.6.4 Puregon (Organon) Recombinant FSH Injections Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.6.5 Puregon (Organon) Recent Developments/Updates
7.6.6 Puregon (Organon) Competitive Strengths & Weaknesses
7.7 BEMFOLA (Gedeon Richter)
7.7.1 BEMFOLA (Gedeon Richter) Details
7.7.2 BEMFOLA (Gedeon Richter) Major Business
7.7.3 BEMFOLA (Gedeon Richter) Recombinant FSH Injections Product and Services
7.7.4 BEMFOLA (Gedeon Richter) Recombinant FSH Injections Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.7.5 BEMFOLA (Gedeon Richter) Recent Developments/Updates
7.7.6 BEMFOLA (Gedeon Richter) Competitive Strengths & Weaknesses
7.8 Follitrope (LG Chem)
7.8.1 Follitrope (LG Chem) Details
7.8.2 Follitrope (LG Chem) Major Business
7.8.3 Follitrope (LG Chem) Recombinant FSH Injections Product and Services
7.8.4 Follitrope (LG Chem) Recombinant FSH Injections Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.8.5 Follitrope (LG Chem) Recent Developments/Updates
7.8.6 Follitrope (LG Chem) Competitive Strengths & Weaknesses
7.9 GenSci
7.9.1 GenSci Details
7.9.2 GenSci Major Business
7.9.3 GenSci Recombinant FSH Injections Product and Services
7.9.4 GenSci Recombinant FSH Injections Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.9.5 GenSci Recent Developments/Updates
7.9.6 GenSci Competitive Strengths & Weaknesses
8 Industry Chain Analysis
8.1 Recombinant FSH Injections Industry Chain
8.2 Recombinant FSH Injections Upstream Analysis
8.2.1 Recombinant FSH Injections Core Raw Materials
8.2.2 Main Manufacturers of Recombinant FSH Injections Core Raw Materials
8.3 Midstream Analysis
8.4 Downstream Analysis
8.5 Recombinant FSH Injections Production Mode
8.6 Recombinant FSH Injections Procurement Model
8.7 Recombinant FSH Injections Industry Sales Model and Sales Channels
8.7.1 Recombinant FSH Injections Sales Model
8.7.2 Recombinant FSH Injections Typical Customers
9 Research Findings and Conclusion
10 Appendix
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer

Companies Mentioned:

Gonal-F (Merck)
Follistim (Organon)
Bravelle (Ferring)
Menopur (Ferring)
Fostimon (IBSA)
Puregon (Organon)
BEMFOLA (Gedeon Richter)
Follitrope (LG Chem)
GenSci

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂